|
Drug Development
|
|
Ethics in Ophthalmics Clinical Trials
Chairperson: R. Vogel
|
|
| |
|
| |
Introduction: A new place
or an old place - the current ethical dilemmas for clinical
study design for ophthalmic products
R. Vogel
|
|
| |
|
|
| |
Addressing ethical implications
of clinical studies
V. Isitt |
|
| |
|
|
| |
Ethics in clinical research
- the physician's perspective
M. Vandenburg
|
|
| |
|
|
| |
Panel discussion
V. Isitt, M. Vandenburg, W. Chamber, M. De Smet,
E. Cunningham
|
|
| |
|
|
| |
|
|
Ophthalmology Drugs - Market Analysis
Chairpersons: E. Strahlman |
Back
to
Section List page |
| |
|
| |
The pricing &
reimbursement of ophthalmological products in Europe.
Current situation and future hurdles
C. Teale
|
|
| |
|
|
| |
|
|
| |
Pharmacogenomics
|
|
| |
|
|
| |
PHARMACOGENETICS ENTERING THE CLINICAL TRIALS ARENA
D. Goldstaub |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
